{"id":"NCT00649792","sponsor":"Acorda Therapeutics","briefTitle":"Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial","officialTitle":"Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-08","primaryCompletion":"2011-01","completion":"2011-04","firstPosted":"2008-04-01","resultsPosted":"2012-02-27","lastUpdate":"2012-02-28"},"enrollment":214,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Fampridine-SR","otherNames":["4-aminopyridine"]}],"arms":[],"summary":"The purpose of the study is to evaluate the safety, tolerability and activity of Fampridine-SR when administered for up to 36 additional months in patients who previously participated in the MS-F204 study or until it becomes commercially available, whichever comes first.","primaryOutcome":{"measure":"Summary of Treatment Emergent Adverse Events (TEAE).","timeFrame":"up to 40 months","effectByArm":[{"arm":"Fampridine-SR","deltaMin":205,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":10},"locations":{"siteCount":42,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":["http://www.acorda.com/clinical.asp"]},"adverseEventsSummary":{"seriousAny":{"events":39,"n":214},"commonTop":["Fall","Urinary Tract Infection","Multiple Sclerosis Relapse","Muscular Weakness","Fatique"]}}